Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma, J. Clin. Endocrinol. Metab, vol.90, pp.6077-6084, 2005. ,
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody, J. Nucl. Med, vol.39, pp.1172-1178, 1998. ,
Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate, Cancer Res, vol.59, pp.4400-4405, 1999. ,
In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer, Cancer Res, vol.54, pp.3479-3486, 1994. ,
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies, Mol. Cancer Ther, vol.1, pp.553-563, 2002. ,
French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group, J. Clin. Oncol, vol.24, pp.1705-1711, 2006. ,
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma, J. Nucl. Med, vol.40, pp.591-603, 1999. ,
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, Eur. J. Nucl. Med. Mol. Imaging, vol.38, pp.2153-2164, 2011. ,
Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens, J. Nucl. Med, vol.39, pp.1937-1943, 1998. ,
Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131 I-labeled bivalent hapten, J. Nucl. Med, vol.41, pp.480-487, 2000. ,
Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188 Re-labeled bivalent hapten: biodistribution and dosimetry studies, J. Nucl. Med, vol.42, pp.146-153, 2001. ,
Perspectives on oncologic imaging with radiolabeled antibodies, Cancer, vol.80, pp.2431-2435, 1997. ,
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?, Eur. J. Nucl. Med. Mol. Imaging, vol.30, pp.777-780, 2003. ,
Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G, Cancer Res, vol.34, pp.1-9, 1974. ,
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J. Clin. Oncol, vol.24, pp.823-834, 2006. ,
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens, J. Nucl. Med, vol.29, pp.226-234, 1988. ,
Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake, J. Nucl. Med, vol.33, pp.2006-2013, 1992. ,
Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in, BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy, Cancer Res, vol.54, pp.5937-5946, 1994. ,
New antibody conjugates in cancer therapy, ScientificWorldJournal, vol.10, pp.2070-2089, 2010. ,
Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation, Clin. Cancer Res, vol.13, pp.1374-1382, 2007. ,
Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy, Bioconjug. Chem, vol.8, pp.526-533, 1997. ,
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90 Y-IMP-288 alone and combined with gemcitabine, J. Nucl. Med, vol.50, 2008. ,
Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.256, pp.495-497, 1975. ,
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial, Clin Cancer Res, vol.5, pp.3190-3198, 1999. ,
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J. Nucl. Med, vol.40, pp.198-204, 1999. ,
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x antihapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial, Clin Cancer Res, vol.9, pp.3973-3981, 2003. ,
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial, J. Nucl. Med, vol.47, pp.247-255, 2006. ,
Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies, Int. J. Cancer, vol.75, pp.74-80, 1998. ,
Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response, J. Nucl. Med, vol.34, pp.1662-1671, 1993. ,
Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice, Cancer Res, vol.50, p.6115, 1990. ,
In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate, J. Nucl. Med, vol.30, pp.1358-1366, 1989. ,
Noncovalent antibody-mediated drug delivery, Nucl. Med. Commun, vol.15, pp.483-491, 1994. ,
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, vol.90, pp.2188-2195, 1997. ,
A novel method of 18 F radiolabeling for PET, J. Nucl. Med, vol.50, pp.991-998, 2009. ,
Bispecific antibody pretargeting PET (immunoPET) with an 124 I-labeled hapten-peptide, J. Nucl. Med, vol.47, pp.1678-1688, 2006. ,
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer, J. Clin. Endocrinol. Metab, vol.90, pp.779-788, 2005. ,
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?, Eur. J. Nucl. Med. Mol. Imaging, vol.30, pp.773-776, 2003. ,
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients, Cancer Res, vol.51, pp.5960-5966, 1991. ,
Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J. Nucl. Med, vol.34, pp.1267-1273, 1993. ,
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, 2006. ,
, Proc. Natl. Acad. Sci. U.S.A, vol.103, pp.6841-6846
18 F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1501-1510, 2014. ,
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J. Nucl. Med, vol.53, pp.1185-1192, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00932253
Development of an imaging-guided CEApretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br. J. Cancer, vol.109, pp.934-942, 2013. ,
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68 Ga-and 18 F-labeled hapten peptide in mice with human tumor xenografts, Mol. Cancer Ther, vol.9, pp.1019-1027, 2010. ,
Pretargeted 177 Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice, J. Nucl. Med, vol.51, pp.1780-1787, 2010. ,
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1593-1602, 2014. ,
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer, J. Nucl. Med, vol.53, pp.1926-1932, 2012. ,
Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies, Cancer Res, vol.61, pp.3712-3717, 2001. ,
A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-363, 2003. ,
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers, J. Nucl. Med, vol.53, pp.1625-1632, 2012. ,
Bifunctional antibody: a binary radio-pharmaceutical delivery system for imaging colo-rectal carcinoma, Cancer Res, vol.51, pp.6650-6655, 1991. ,
Immuno-positron emission tomography: shedding light on clinical antibody therapy, Cancer Biother. Radiopharm, vol.25, pp.375-385, 2010. ,
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody, Eur. J. Nucl. Med. Mol. Imaging, vol.40, pp.1377-1383, 2013. ,
89 Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals, Curr. Top. Med. Chem, vol.13, pp.446-457, 2013. ,
Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J. Nucl. Med, vol.38, pp.507-511, 1997. ,
Radioimmunotherapy: recent results and future directions, J. Clin. Oncol, vol.14, pp.1383-1400, 1996. ,
, Conflict of Interest Statement: Dr. Sharkey is an employee of Immunomedics, Inc. Dr. Goldenberg is stockholder and officer of Immunomedics
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, 2015. ,